Pfizer Inc. (PFE) — closed signal from September 5, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 4, 2025.
Predicted vs. what happened
What happened
Reached its target in 26 days.
The thesis — published September 5, 2025
Pfizer's stock looks beaten down, and more buyers than usual seem to be stepping in, which can lift prices even if some trend signs are weak. Demand helps: markets for freeze-dried injections are growing about 14% a year, and immune-therapy products about 6.7%. Politics around mRNA funding may add noise. Over the next 3 months, its dividend and fair price make a bounce toward normal more likely.
Primary drivers
- Price looks beaten down, while investor mood and trading interest are strong
- Key drug formats like freeze-dried shots and immune therapies are growing
- A solid dividend and a reasonable price help limit how far shares may fall
- Political debate around mRNA funding could cause short-term ups and downs
How it played out
PFE: target reached in 26 days
Lyra published PFE at 24.25 on 2025-09-05 with a short-term thesis for 10% growth. The thesis pointed to a beaten-down price, stronger trading interest, growth in freeze-dried injections of about 14% a year, immune-therapy products at about 6.7%, dividend support, fair price, and possible mRNA funding noise.
Inside the window, PFE reached the 26.22 target in 26 days. The peak was 27.21 on 2025-10-03, with a 12.2% gain. It ended the window at 25.70. The published thesis played out.
What happened during the window
On September 30, 2025, Pfizer and the Trump administration announced a drug-pricing agreement tied to Medicaid pricing and TrumpRx. Politico reported that Pfizer also said it planned $70 billion in U.S. research, development, and infrastructure spending.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.